Global company, Globus, announces Keith Pfeil as its new CEO, with previous executive departing to join Dentsply.
Globus Medical, a prominent player in the musculoskeletal technology market, has announced a significant leadership transition, with Keith Pfeil taking over as President and CEO, effective from July 18, 2025. Pfeil, who has been with the company since 2019, has held various key positions including Senior Vice President and CFO, Executive Vice President, COO, and CFO. His appointment comes after Daniel Scavilla's resignation after ten years as CEO to pursue another opportunity.
Scavilla's departure is viewed as a planned leadership transition rather than a performance-based decision. He publicly praised Pfeil and expressed pride in having been part of Globus, wishing the company continued success under Pfeil's leadership.
The leadership change coincides with strong financial performance. Globus reported preliminary Q2 2025 sales of approximately $745.3 million, an 18.4% increase year-over-year. The impressive growth is attributed to strong spine growth and the impact of the Nevro acquisition, a spinal cord stimulation business Globus bought for $250 million in February.
Alongside Pfeil's promotion, Kyle Kline was elevated to Senior Vice President and CFO to continue financial leadership. RBC analysts consider Kline as part of Globus Medical's internal succession plan.
Despite the stock market's initial reaction, RBC analysts believe the stock reaction was overdone, reflecting their confidence in Globus' internal succession plan. They also consider the timing of Scavilla's departure and Dentsply's appointment of him as CEO as less 'suspect' due to the circumstances.
Pfeil expressed gratitude for the opportunity and emphasized continuing Globus’s culture of innovation and teamwork. He looks forward to leading the company in its continued growth and success.
[1] Globus Medical Press Release, July 18, 2025. [2] Daniel Scavilla's Statement, July 18, 2025. [3] RBC Capital Markets Research Report, July 19, 2025. [4] Truist Securities Research Report, July 19, 2025.
- The news of Keith Pfeil's promotion to President and CEO of Globus Medical, following Scavilla's departure, is a testament to the company's commitment to medtech analytics and AI, as they continue to innovate and grow in the business and finance sectors.
- As Pfeil assumes leadership, the company's focus on devices, particularly in the musculoskeletal technology market, is expected to drive further trends in the industry, given Globus' impressive financial performance.
- The financial stability of the company, evident in the strong Q2 sales of $745.3 million, suggests a thriving relationship with finance and business, as RBC analysts believe the stock market's initial reaction was overly reactionary.
- The elevation of Kyle Kline to Senior Vice President and CFO indicates a strategic approach to succession planning within Globus Medical, which aligns with the company's drive for continued growth and success in the medtech industry.
